Cumberland Pharmaceuticals
CompanyUnited States
Cumberland Pharmaceuticals develops 2 assets, the furthest approved (acetylcysteine). Mostly small molecule acting on Oxidative stress and ROS signalling, AMPK signalling and lipid and ceramide metabolism; based in the United States.
- Assets
- 2
- Furthest
- Approved
- Trials
- 2
- Signals
- 0
Pipeline
2Glutathione precursor and mucolytic agent with antioxidant properties.
ApprovedSmall moleculeOxidative stress and ROS signallingabnormal mucus secretion (Phase 3)acetaminophen overdose (Phase 3)
HMG-CoA reductase inhibitor that suppresses cholesterol biosynthesis and lowers plasma LDL levels
ApprovedSmall moleculeAMPK signallingLipid and ceramide metabolismanginacoronary heart disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms7
- Trials4
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 73 sources